Figure S3

Sample_ID	306_T1	314_T1	260_T1	358_T1	387_T1	372_T1	434_T1	516_T1	376_T2	532_T1	552_T1	515_T1	567_T1	614_T1	361_T1	327_T1	509_T1	452_T2		473_T1	459_Archival1	330_T1	185_T1	394_T2	294_T2	195_T1	333_T1	177_Prospective1	398_T1	191_T1	538_T1	329_T1	346_T1	386_T1	315_T1	338_T1	299_T1	290_T2	350_T1	307_T1	535_T1	303_T1	357_T1	292_T1	401_T1	430_T1	391_T1	385_T1	383_T1	381_T1	397_T1	295_T1	568_T1	349_T1	408_T1A	408_T1B	496_T1	606_T1	366_T2	331_T1	TOTAL
Biopsy_Phenotype	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S		IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	
AKT1 Activation										1																					1																			1					1	1			1		6
AURKA Amplification																				1						1	1			1	1											1		1							1	1		1					1		11
Biallelic RB1 Disruption																							1				1																				1					1									4
CCNE2 Amplification									1											1						1							1	1						1						1															7
ER Loss																						1																									1													1	3
ERBB2 Activation					1																														1												1						1		1						1	6
FGFR2 Activation																																	1						1	1																					3
RAS Activation																													1									1								1														1	4
TOTAL	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0		2	0	1	1	0	0	2	2	0	1	1	2	0	2	1	1	0	0	1	1	2	0	1	0	1	0	2	3	0	0	1	1	2	1	2	1	1	0	0	2	3	

Supplemental Figure 3. Mutual Exclusivity Analysis Amongst Putative Resistance Driver Alterations

The presence of the eight driver alterations highlighted in the manuscript is provided for each patient biopsy sample. These alterations include (alphabetically): AKT1 activation, AURKA amplification, biallelic RB1 disruption, CCNE2 amplification, ER loss (via IHC), ERBB2 activation, FGFR2 activation, and RAS activation (including HRAS, KRAS, and NRAS). For each biopsy specimen, the total number of potential driver alterations is tallied.